EpiVax Oncology Appoints Daniel Adams as Chairman of the Board of Directors

“I am thrilled and honored to have Dan Adams becoming the Chairman of EpiVax Oncology’s Board of Directors. Adding such an illustrious biotechnology industry executive with the broad experience and successful track record of Dan to our board further strengthens our leadership team, while providing further validation for our novel cancer precision immunotherapy approach and clinical-stage development program,” said EpiVax Oncology CEO, Gad Berdugo, MSc Eng., MBA. “We look forward to Dan’s insight and expertise complementing that of the existing board members as we work to successfully advance into the clinic. His operational and corporate development experience will undoubtedly prove valuable.”

“EpiVax Oncology’s focus on neoantigens represents an entirely new, more precise and potentially safer way to address difficult to treat cancers,” said Daniel Adams, JD. He added, “The technology that we in-licensed from EpiVax Inc. that it developed over more than 20 years, represents in my opinion a significant advance over competing technologies in precision, speed and accuracy in identifying the right neoantigens and delivering them to patients in a few weeks.”

Dan Adams is the Executive Chairman and Co‐Founder of NextWaveBio, a next‐generation biotechnology enterprise developing safer, more affordable pharmaceuticals. Mr. Adams served as CEO then as the Executive Chairman of Protein Sciences Corporation, a leader in developing and manufacturing vaccines, therapeutics and diagnostics, including Flublok^®, a patented, first in class recombinant influenza vaccine, that received licensure from FDA in 2013. The Company was acquired by Sanofi for approximately $750 million. Previously Dan founded and managed several biotechnology companies including Biogen that achieved a combined value of well in excess of $60 billion.

About EpiVax Oncology, Inc.

EpiVax Oncology, Inc. is a privately-held biotechnology company focusing on developing precision cancer immunotherapies based in New York City, NY. Incorporated in 2017, EpiVax Oncology is a spin-out of EpiVax Inc., a company founded by Dr. Annie De Groot and Mr. Bill Martin in 1998. EpiVax Oncology is leveraging EpiVax's 20 years of experience in designing commercial-grade immunoinformatic tools, to advance its personalized therapeutic cancer vaccine development program. EpiVax Oncology's personalized vaccine design platform, Ancer™, incorporates the world-class EpiMatrix^® system and the innovative JanusMatrix™ tool, which were exclusively licensed to EpiVax Oncology by EpiVax. More information about EpiVax Oncology is available at www.epivaxoncology.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200127005083/en/